Co-Diagnostics, Inc. to Present at Utah Mosquito Abatement Association Conference
October 29, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics
company with a unique, proprietary platform for the development of
molecular diagnostic tests, announced today that it will be offering a
presentation of its mosquito vector control program at the 71st
Annual Utah Mosquito Abatement Association conference in Ogden, Utah on
October 29, 2018.
From
the website of the Utah Mosquito Abatement Association (UMAA), the
UMAA was founded in 1948, with the goal of promoting close cooperation
among those concerned with, or interested in mosquito control and
related work, to increase the knowledge and advance the cause of
mosquito abatement in an efficient and effective manner compatible with
the goals of a sound environment.
Vector is the term used to describe an organism that transmits
infectious disease across human or animal populations. Co-Diagnostics’
vector control program will involve technology provided by the Company
for use in vector control services to test mosquito populations where
the insect is known or suspected to act as a vector. The UMAA conference
will include a brief presentation of the technology used by the Company
in vector control programs, as well as meetings with several department
heads and directors of organizations across the state involved with
control and abatement of mosquitos carrying diseases like West Nile
virus.
Co-Diagnostics CEO Dwight Egan commented, “We believe Co-Diagnostics is
an ideal partner to provide support in pairing disease detection with
vector control programs. Our proprietary design platform allows us to
provide products that meet this demand via patented, state-of-the-art
technology that represents a leap forward in the understanding of
real-time PCR molecular diagnostics. Tests used in vector control
programs are not intended to diagnose humans, and are therefore subject
to different regulatory requirements. This will allow our products to be
manufactured locally in the Company’s ISO 13485:2016 facility, and sold
throughout the United States without 510(k) clearance or Premarket
Authorization (“PMA”) from the FDA.
“The opportunity to provide vector control tests extends throughout vast
regions of the world that are home to more than 2 billion people who are
vulnerable to serious infections from mosquitoes. Co-Diagnostics has
many tests completed or in development with direct vector control
applications, including those for Zika, tuberculosis, malaria, and
Zika/dengue/chikungunya multiplex, among others.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics
company with a proprietary diagnostic testing technology and development
platform that intends to manufacture and sell reagents used for
diagnostic tests that function via the detection and/or analysis of
nucleic acid molecules (DNA or RNA), and license the use of its platform
to other non-competing developers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
“believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will”
and similar expressions, or the negative of these words. Such
forward-looking statements are based on facts and conditions as they
exist at the time such statements are made and predictions as to future
facts and conditions. Forward-looking statements in this release
include statements regarding the (i) use of funding proceeds, (ii)
expansion of product distribution, (iii) acceleration of initiatives in
liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in the
near-term, (vii) flexibility in managing the Company’s balance sheet,
(viii) anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements are
subject to inherent uncertainties, risks and changes in circumstances.
Actual results may differ materially from those contemplated or
anticipated by such forward-looking statements. Readers of this press
release are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this press
release, except as may be required by applicable securities laws.
Contacts
Company Contact:
Co-Diagnostics, Inc.
Andrew Benson
Co-Diagnostics
Investor Relations
801-438-1036
investors@codiagnostics.com
or
Investor
Contact:
Lytham Partners, LLC
Joe Diaz, Robert Blum and
Joe Dorame
602-889-9700
codx@lythampartners.com